Pathogenic approach to treating patients with primary dysmenorrhea


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the data of modern literature on the etiology and pathogenesis of dysmenorrhea, by substantiating and optimizing the treatment of patients with primary dysmenorrhea. Material and methods. The review included the data of foreign and Russian articles published over the past 10 years and found in Pubmed on this topic. Results. Thus, dysmenorrhea is a rather common disease that reduces quality of life, the main cause of which is overproduction of prostaglandins, hormonal imbalance (abnormal estradiol/progesterone ratio), stressful states, and depression (reduced gamma aminobutyric acid levels). Conclusion. Nonsteroidal anti-inflammatory drugs and combined oral contraceptives proved to be effective and pathogenetically sound drugs used for the therapy of primary dysmenorrhea.

Full Text

Restricted Access

About the authors

Natalia A. Buralkina

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: natalyaburalkina@yandex.ru
MD, Senior Researcher, 2nd gynecological department

Maria Yu. Borisenko

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: mary-sm@mail.ru
postgraduate student of 3rd year of study, an employee of the 2nd gynecological department

Naila H. Latypova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: nlatipova@mail.ru
PhD, doctor of the 2nd gynecological department

References

  1. Межевитинова Е.А., Абакарова П.Р., Мгерян А.Н. Дисменорея с позиций доказательной медицины. Consilium medicum. 2014; 16(6): 83-7. [Mezhevitinova E.A., Abakarova P.R., Mgeryan A.N. Dysmenorrhea from the standpoint of evidence-based medicine. Consilium medicum. 2014; 16 (6): 83-7. (in Russian)]
  2. Mrugacz G., Grygoruk C., Sieczynski P., Grusza M., Bolkun I., Pietrewicz P. Etiopathogenesis of dysmenorrheal. Med. Wieku Rozwoj. 2013; 17(1): 85-99.
  3. Osayande A.S., Mehulic S. Diagnosis and initial management of dysmenorrhea. Am. Fam. Physician. 2014; 89(5): 341-6.
  4. Woosley J.A., Lichstein K.L. Dysmenorrhea, the menstrual cycle, and sleep. Behav. Med. 2014; 40(1): 14-21.
  5. Паренкова И.А., Коколина В.Ф., Румянцева А.Г. Качество жизни у девочек-подростков с первичной дисменореей. Репродуктивное здоровье детей и подростков. 2011; 6: 49-60. [Parenkova I.A., Kokolina V.F., Rumyantseva A.G. The quality of life in adolescents with primary dysmenorrhea. Reproduktivnoe zdorove detey i podrostkov. 2011; 6: 49-60. (in Russian)]
  6. Kural M., Noor N.N., Pandit D., Joshi T., Patil A. Menstrual characteristics and prevalence of dysmenorrhea in college going girls. J. Fam. Med. Prim. Care. 2015; 4(3): 426-31.
  7. Morrison B.W., Daniels S.E., Kotey P., Cantu N., Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet. Gynecol. 1999; 94(4): 504-8.
  8. Liedman R., Grant L., Igidbashian S., James I., McLeod A., Skillern L., Akerlund M. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrheal. Acta Obstet. Gynecol. Scand. 2006; 85(2): 207-11.
  9. Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol. Endocrinol. 1989; 3(1): 71-94.
  10. Liedman R., Hansson S.R., Howe D., Igidbashian S., McLeod A., Russell R.J., Akerlund M. Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects. Gynecol. Endocrinol. 2008; 24(9): 508-13.
  11. Proctor M., Farquhar C. Dysmenorrhoea. Clin. Evid. 2012; (7): 1639-53.
  12. Bonney R.C., Qizilbash S.T., Franks S. Endometrial phospholipase A2 enzymes and their regulation by steroid hormones. J. Steroid Biochem. 1987; 27(4-6): 1057-64.
  13. Schatz F., Markiewicz L., Gurpide E. Estradiol enhances prostaglandin synthase activity in epithelial but not in stromal cells of human endometrium. J. Steroid Biochem. 1987; 27(4-6): 1065-71.
  14. Уварова Е.В. Дисменорея (альгоменорея). В кн.: Богданова Е.А., ред. Гинекология детей и подростков. М.: МИА; 2000: 245-60. [Uvarova E.V. Dysmenorrhea (algomenoreya). In: Bogdanova E.A., eds. Gynecology children and adolescents. Moscow: MIA; 2000: 245-60. (in Russian)]
  15. Xu K., Chen L., Fu L., Xu S., Fan H., Gao Q. et al. Stressful parental-bonding exaggerates the functional and emotional disturbances of primary dysmenorrhea. Int. J. Behav. Med. 2015; Aug 26.
  16. Yui K., Imataka G., Nakamura H., Ohara N., Naito Y. Eicosanoids derived from arachidonic acid and their family prostaglandins and cyclooxygenase in psychiatric disorders. Curr. Neuropharmacol. 2015; 13(6): 776-85.
  17. Onaka Y., Shintani N., Nakazawa T., Haba R., Ago Y., Wang H. et al. CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice. Behav. Brain Res. 2015; 284: 131-7.
  18. Moldavan M., Cravetchi O., Williams M., Irwin R.P., Aicher S.A., Allen C.N. Localization and expression of GABA transporters in the suprachiasmatic nucleus. Eur. J. Neurosci. 2015; 42(12): 3018-32.
  19. Marjoribanks J., Proctor M.L., Farquhar C., Derks R.S. Nonsteroidal antiinflammatory drugs for dysmenorrhea. Cochrane Database Syst. Rev. 2010; (1): CD001751.
  20. Dawood M.Y. Primary dysmenorrhea: advances in pathogenesis and management. Obstet. Gynecol. 2006; 108(2): 428-41.
  21. Grandi G., Napolitano A., Xholli A., Tirelli A., Di Carlo C., Cagnacci A. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinylestradiol and chlormadinone acetate on primary dysmenorrhea. Gynecol. Endocrinol. 2015; 31(10): 774-8.
  22. Huber J.C., Heskamp M.L., Schramm G.A. Effect of an oral contraceptive with chlormadinone acetate on depressive mood: analysis of data from four observational studies. Clin. Drug Investig. 2008; 28(12): 783-91.
  23. Pushparajah D.S., Röhm P., Höschen K., Albers D., Nowack C. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/ chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice. Clin. Drug Investig. 2011; 31(2): 121-34.
  24. Brucker C., Hedon B., The H.S., Höschen K., Binder N., Christoph A. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception. 2010; 81(6): 501-9.
  25. Schramm G.A., Schrah G. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women. Contraception. 2011; 84(4): 390-401.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies